Ireland· IE-PA-EU/1/19/1360/001-002
Waylivra 285 mg Solution for injection
A volanesorsen product containing volanesorsen sodium, registered in Ireland by Akcea Therapeutics Ireland Ltd. The same ATC class is registered in 11 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Volanesorsen is registered in 11 of 19 countries.
Countries holding a registration under ATC C10AX18 (volanesorsen), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Volanesorsen · ATC C10AX18
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- United Kingdom
The record
At a glance
HPRA (Ireland)- Active substance
- VOLANESORSEN SODIUM
- Manufacturer
- Akcea Therapeutics Ireland Ltd
- Country
- Ireland (IE)
- ATC code
- C10AX18
- ATC class
- Volanesorsen
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/19/1360/001-002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Volanesorsen in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaWAYLIVRAAkcea Therapeutics Ireland Ltd, Dublin
- BelgiumWaylivra 285 mgAkcea Therapeutics Ireland
- FinlandWaylivraAkcea Therapeutics Ireland Ltd
- SwedenWaylivra 285 mg Injektionsvätska, lösning i förfylld sprutaAkcea Therapeutics Ireland Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Waylivra
- Liechtenstein · Waylivra
- Norway · Waylivra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9db311f9-2631-4cbf-a733-f117a3eecc90 GET /v1/drugs/9db311f9-2631-4cbf-a733-f117a3eecc90?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled syringe",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"C10AX18"
],
"strength": null,
"pa_number": "EU/1/19/1360/001-002",
"substances": [
"VOLANESORSEN SODIUM"
],
"legal_basis": "New active substance (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "03/05/2019",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about volanesorsen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.